Skip to main content

Table 2 Drug-drug interactions and combination index (CI) of ODCs in 3D models

From: Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma

  

ODCSW620

ODCLS174T

ODCSWFXR

ODCLSFXR

TGMO

Synergisms

reg:azd

erl:lap

lap:nilo

palb:azd

reg:palb

CI

ODC

0.42

0.11

0.006

0.27

  1. Drugs: reg, regorafenib, azd, AZD-4547; erl, erlotinib; lap, lapatinib; palb, palbociclib; nilo, nilotinib. CI < 1: synergistic drug combination, CI > 1: antagonistic drug combination
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us